Novo, Lilly and Zealand showed amylin trial data in Milan. CagriSema hit 22.4% average weight loss in a trial and has an FDA decision expected by year end.
Recap by typeshit. Full story at qz.com.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
He says his blood work came in half a point from a diabetic result, which scared him into starting the drug. A personal account, not medical advice.
Josh Holyfield argues that appetite suppression isn't the most important effect of retatrutide for anyone trying to change body composition. These are his views, not trial findings.
Loading…